Cobimetinib, racemic mixture 13C6
| Product Name | Cobimetinib, racemic mixture 13C6 |
|---|---|
| Alternate Names | Cobimetinib Stable Isotopes, Stable Isotopes of Cobimetinib |
| CAT No. | CS-EK-02386 |
| CAS No. | 934662-91-6 unlabeled |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Cobimetinib |
| Canonical Smiles | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
| InchIKey | BSMCAPRUBJMWDF-UHFFFAOYSA-N |
| Inchl | InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2 |
| IUPAC | [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-piperidin-2-ylazetidin-1-yl)methanone |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
[13C6]-Cobimetinib, racemic mixture is a chemical compound that is widely used in the pharmaceutical industry for the treatment of cancer. It is a kinase inhibitor that works by selectively blocking the activity of mitogen-activated protein kinase (MEK), which is a key component of the Ras/Raf/MEK/ERK signaling pathway.
This pathway is often overactive in cancer cells, leading to uncontrolled cell growth and proliferation. By inhibiting MEK, [13C6]-Cobimetinib can slow down or stop the growth of cancer cells, thereby improving the efficacy of chemotherapy and other cancer treatments.
Chemically, [13C6]-Cobimetinib is a racemic mixture, meaning it contains equal amounts of two enantiomers that are mirror images of each other. These enantiomers have the same chemical formula and molecular weight, but their spatial arrangement is different, which can affect their biological activity and pharmacokinetics.
[13C6]-Cobimetinib is labeled with six carbon-13 isotopes, which can be used in metabolic studies to track the fate of the drug in the body. This labeling technique can provide valuable information on the absorption, distribution, metabolism, and excretion (ADME) of the drug, which can help optimize its dosing and minimize its side effects.
Overall, [13C6]-Cobimetinib, racemic mixture is a promising drug candidate that has shown great potential in the treatment of various types of cancer. Its unique chemical properties make it a valuable tool for understanding its pharmacokinetics and optimizing its therapeutic effects.
Get an Instant Quote
Related Compounds
Cobimetinib-D4 HCl | Cobimetinib D9 | Cobimetinib-D4 |